$BLRX Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.00
• Reported revenue of $0.29M down -3.33% YoY
• BioLineRx is maintaining its cash runway guidance into the first half of 2027, supported by $13.1M in cash, cash equivalents, and short-term bank deposits as of June 30, 2026.